Rajesh Kumar
Stock Analyst at HSBC
(2.42)
# 2,489
Out of 5,245 analysts
33
Total ratings
40.91%
Success rate
4.66%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,070 → $850 | $1,065.00 | -20.19% | 4 | Mar 17, 2026 | |
| PFE Pfizer | Maintains: Buy | $29 → $32 | $25.90 | +23.55% | 2 | Mar 17, 2026 | |
| BIIB Biogen | Maintains: Reduce | $143 → $150 | $193.76 | -22.58% | 2 | Mar 17, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $60 | $59.46 | +0.91% | 3 | Mar 17, 2026 | |
| ABBV AbbVie | Upgrades: Buy | $225 → $265 | $215.70 | +22.86% | 5 | Dec 10, 2025 | |
| NVO Novo Nordisk | Downgrades: Hold | n/a | $44.96 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $167.90 | +39.96% | 2 | Oct 9, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $29.12 | +44.23% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $448.28 | +49.46% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $172.00 | +62.79% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $460 | $388.47 | +18.41% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $34.07 | -61.84% | 1 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $46.88 | +106.91% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $92.14 | +34.58% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $122.41 | +0.48% | 1 | Jul 14, 2023 |
Eli Lilly and Company
Mar 17, 2026
Downgrades: Reduce
Price Target: $1,070 → $850
Current: $1,065.00
Upside: -20.19%
Pfizer
Mar 17, 2026
Maintains: Buy
Price Target: $29 → $32
Current: $25.90
Upside: +23.55%
Biogen
Mar 17, 2026
Maintains: Reduce
Price Target: $143 → $150
Current: $193.76
Upside: -22.58%
Bristol-Myers Squibb Company
Mar 17, 2026
Maintains: Hold
Price Target: $53 → $60
Current: $59.46
Upside: +0.91%
AbbVie
Dec 10, 2025
Upgrades: Buy
Price Target: $225 → $265
Current: $215.70
Upside: +22.86%
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $44.96
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $167.90
Upside: +39.96%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $29.12
Upside: +44.23%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $448.28
Upside: +49.46%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $172.00
Upside: +62.79%
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $388.47
Upside: +18.41%
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $34.07
Upside: -61.84%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $46.88
Upside: +106.91%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $92.14
Upside: +34.58%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $122.41
Upside: +0.48%